We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $652M
1-Year Est. Return 198.07%
This Fund
S&P 500
This Quarter Est. Return
+4.85%
1 Year Est. Return
+198.07%
3 Year Est. Return
+299.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$334M
AUM Growth
-$7.78M
Cap. Flow
-$9
Cap. Flow %
-0%
Top 10 Hldgs %
97.27%
Holding
20
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$9

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
1
Protagonist Therapeutics
PTGX
$9.06B
$136M 40.83%
2,449,183
– –
MGTX icon
2
MeiraGTx Holdings
MGTX
$1.15B
$43.9M 13.14%
6,641,064
– –
RAPP
3
Rapport Therapeutics
RAPP
$2.04B
$28.6M 8.55%
2,498,051
– –
LEGN icon
4
Legend Biotech
LEGN
$4.31B
$28.2M 8.44%
814,586
– –
NBTX
5
Nanobiotix
NBTX
$1.92B
$25.5M 7.62%
5,623,816
– –
CVRX icon
6
CVRx
CVRX
$130M
$23.9M 7.15%
4,103,430
– –
PRCT icon
7
Procept Biorobotics
PRCT
$1.09B
$20.4M 6.1%
357,939
– –
CTNM
8
Contineum Therapeutics
CTNM
$532M
$8.13M 2.43%
1,979,173
– –
XNCR icon
9
Xencor
XNCR
$1.3B
$6.09M 1.82%
748,062
– –
ARWR icon
10
Arrowhead Research
ARWR
$10.5B
$3.98M 1.19%
247,598
– –
FATE icon
11
Fate Therapeutics
FATE
$324M
$3.51M 1.05%
3,379,064
– –
NMRA icon
12
Neumora Therapeutics
NMRA
$298M
$1.4M 0.42%
1,849,445
– –
RLYB icon
13
Rallybio
RLYB
$87.1M
$1.21M 0.36%
454,545
– –
VOR icon
14
Vor Biopharma
VOR
$980M
$1.14M 0.34%
53,733
– –
NNOX icon
15
Nano X Imaging
NNOX
$78M
$831K 0.25%
158,852
– –
LAB icon
16
Standard BioTools
LAB
$350M
$371K 0.11%
311,967
– –
LYEL icon
17
Lyell Immunopharma
LYEL
$326M
$368K 0.11%
41,165
-1
-0% -$9
ACET icon
18
Adicet Bio
ACET
$75.9M
$228K 0.07%
22,780
– –
PHGE icon
19
BiomX
PHGE
$2.16M
$42.6K 0.01%
5,098
– –
SENS icon
20
Senseonics Holdings Inc
SENS
$267M
$27K 0.01%
2,731
– –

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
FMN
Financial Management Network Mission Viejo, California $653M AUM 17.76% 1-Year Est. Return
NGM
North Growth Management Vancouver, British Columbia, Canada $653M AUM 88.28% 1-Year Est. Return
RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
HFS
Hughes Financial Services Herndon, Virginia $651M AUM 15.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Johnson & Johnson's Q2 2025 Portfolio in Review

As of Q2 2025, Johnson & Johnson held 20 positions worth $334M, down 2.3% from $342M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 0%. Johnson & Johnson opened no new positions and made no exits, leaving the 20-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Johnson & Johnson's biggest Q2 2025 reduction was Lyell Immunopharma, cutting an estimated $9.
  • Johnson & Johnson's ten largest holdings make up 97% of its $334M portfolio in Q2 2025.
  • Johnson & Johnson opened 0 new positions and closed 0 in Q2 2025.
  • Johnson & Johnson's portfolio value fell 2.3% quarter-over-quarter to $334M.

Based on Johnson & Johnson's 13F filing for Q2 2025, filed 22 Jul 2025.